Latest Dermatology News

Page 2 of 6
Doctor Care Anywhere posted an 8.4% quarterly jump in consultations and sustained positive cashflow for the fourth consecutive quarter, while launching new digital health initiatives and reaffirming its medium-term revenue and profitability targets.
Ada Torres
Ada Torres
23 Apr 2026
Noxopharm reports preclinical data revealing SOF-SKN’s active ingredient remains in skin tissues for about 3.5 days with minimal systemic absorption, supporting less frequent dosing and sustained activity for cutaneous lupus treatment.
Ada Torres
Ada Torres
22 Apr 2026
Botanix Pharmaceuticals has agreed to terms with Piramal to establish an alternate supplier for the active ingredient in Sofdra, aiming to reduce costs by up to 40% and strengthen its supply chain.
Ada Torres
Ada Torres
16 Apr 2026
Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.
Ada Torres
Ada Torres
27 Feb 2026
Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.
Ada Torres
Ada Torres
17 Feb 2026
Botanix Pharmaceuticals has secured approximately A$45 million through a two-tranche placement and an underwritten security purchase plan to fund API purchases, derisk its supply chain, and accelerate growth of its flagship product Sofdra.
Ada Torres
Ada Torres
17 Feb 2026
Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.
Victor Sage
Victor Sage
29 Jan 2026
Doctor Care Anywhere reported steady consultation growth and a third consecutive quarter of positive cashflow in Q4 2025, while advancing digital health pilots and reaffirming ambitious medium-term revenue and profitability goals.
Ada Torres
Ada Torres
29 Jan 2026
Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.
Ada Torres
Ada Torres
27 Jan 2026
Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.
Ada Torres
Ada Torres
22 Dec 2025
Mayne Pharma has rejected Cosette Pharmaceuticals’ notice to terminate their merger agreement, citing Cosette’s failure to meet obligations that led to regulatory approval issues. The dispute raises fresh uncertainty over the proposed acquisition’s future.
Ada Torres
Ada Torres
10 Dec 2025
Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.
Ada Torres
Ada Torres
25 Nov 2025

Browse the archive

Full archive